SREBF1 and neoplasm: Yi et al. found that activating the mutation of PI3K can result in ferroptosis resistance in tumor cells, while the expression of SREBP1 or SCD1 can inhibit the PI3K/Akt/mTOR axis by regulating lipid metabolism, which can sensitize the ferroptosis of cancer cells and play an antitumor role (Yi, et al., 2020).